Heart failure affects liver morphology and function. What are the clinical implications?

Goncalvesova E, Kovacova M

The National Institute of Cardiovascular Diseases, Department of heart failure and heart transplantation, Bratislava, Slovakia. eva.goncalvesova@nusch.sk

ABSTRACT
Liver dysfunction in heart failure is common and usually clinically significant, especially in patients with advanced or severe acute heart failure. Lesions are caused by an impaired hepatic circulation due to congestion and hypoperfusion. Congestive lesions are more common and typically manifested by painful hepatomegaly and increased direct bilirubin and alkaline phosphatase. The inferior vena cava and hepatic veins are usually dilated. Congestive lesions are characterized by dilatation of the central vein with fibrotic changes in the surrounding areas on histological examination. Isolated ischaemic lesions are rare and occur due to severe and prolonged ineffective perfusion, often accompanied by hypoxemia. Ineffective perfusion is reflected by an increase in total bilirubin and significantly increased transaminase levels. The prognosis of ischaemic lesions without an adequate treatment of the cause of hypoperfusion is poor. Increased levels of bilirubin and liver function tests, as well as signs of impaired liver proteosynthetic function, are associated with a poor prognosis. Knowledge of the phenotypes of hepatic lesions in heart failure is important to select the appropriate treatment for an acute decompensation. Changes in biochemical markers, hepatic perfusion or stiffness of the liver can be used to evaluate the effectiveness of diuretic treatment and achieve euvolemic status in the patients with heart failure (Tab. 1, Fig. 3, Ref. 28). Text in PDF www.elis.sk.

KEY WORDS: liver dysfunction, heart failure, congestion.

Introduction
Heart failure (HF) is a complex syndrome, when a heart is unable to supply the organs with an adequate volume of oxygen-rich blood and is associated with blood congestion. For these reasons, HF exhibits multiple organ manifestations in its more advanced stages. The liver is damaged very often. This is the result of high metabolic activity associated with a high oxygen demand and anatomical location near the heart associated with a high central venous pressure.

Liver dysfunction in HF was discussed in literature in the first half of the 20th century. In 1930, N. Jolliffe reported that 80 % of patients with congestive HF had elevated levels of bilirubin, and more than 90 % had an impaired hepatic function (1). The awareness of liver dysfunction and the clinical presentation of liver lesions in acute or chronic HF do not correlate with its frequency. For better understanding of the clinical scenario, we added two case reports at the end of this review article.

According to the latest data, total bilirubin levels are increased in 20–26 % of patients admitted to the hospital for acute HF. Increased levels of cholestatic enzymes, especially gamma-glutamyltransferase (GGT) was detected in 62 % of patients (2, 3), and isolated elevation of aspartate aminotransferase and alanine aminotransferase (AST, ALT) was found in 26 % of the patients (4). Among patients with chronic HF, total bilirubin was increased in 13 % and transaminases were increased in 3.1 % of the patients. A decreased level of albumin was detected in 18.3 % of the patients (5).

Hepatic portal circulation

The liver has a high metabolic activity that is dependent on sufficient perfusion (approximately 1 ml/g/min). Approximately 20–25 % of cardiac output flows through the liver at rest. The liver receives a dual blood supply. The hepatic artery supplies fully oxygenated blood to the liver under systemic pressure and delivers approximately 35 % of the liver’s blood supply and 50 % of the liver’s oxygen demand. The portal vein carries blood drained from the splanchnic area and provides not only the metabolic substrates, but also the remaining quantity of the liver’s oxygen demand. Arterial and portal blood are mixed in liver sinusoids (second capillary bed). Liver sinusoids are porous channels connecting the portal areas with the central vein of the hepatic acinus. Central veins drain into gradually expanding hepatic veins. Major hepatic veins flow into the inferior vena cava near the right atrium. The right ventricle filling pressure is thus immediately transferred to the hepatic circulation. The pressure in the portal vein can be measured indirectly by inserting a catheter via the
Pathology and pathophysiology of hepatic lesions in HF

The basic structural unit of the liver is the hepatic lobule, which is composed of a central efferent vein surrounded by lined sinusoids and the portal tracts, which can be found running along each corner of the lobule. Portal tracts, also known as portal triads, consist of terminal branches of the hepatic artery, portal vein and the bile ducts. The functional unit of the liver is the acinus. It is a small part of liver parenchyma, which contains terminal branches of the portal triad as its central axis. Depending on the distance from the portal triad, three zones can be recognized in the acinus. The furthest zone, zone 3, is located around the central vein, receives blood with a low level of oxygen and is sensitive to hypoxia. Increased pressure in the right atrium is transmitted to the hepatic veins and results in dilatation of the sinusoids in zone 3 and the compression of hepatocytes in combination with hypoxia leads to atrophy, necrosis and fibrosis (Figs 1A, B).

Functional changes in the local circulation are present in acute decompensated or advanced HF. α-adrenergic receptors are mostly located in the portal vein and β2 receptors are located in the hepatic veins. Sympathetic activation causes portal vasoconstriction, splanchnic congestion and the worsening of liver ischaemia.

Centrilobular necrosis is a regular finding in hepatic lesions due to HF. If HF worsen, the necrosis spreads peripherally. Successful treatment leads to the healing of necrosis. Initially, fibrotic changes are localized around the central vein. When severe and longstanding hepatic congestion leads to bridging fibrosis between the central veins, it is called cardiac cirrhosis.

The pathological appearance of a liver affected by chronic congestion is ‘speckled’ similar to a grated nutmeg kernel. Nutmeg liver develops typically in cases of a prolonged congestion due to right HF caused by pulmonary arterial hypertension, pulmonary hypertension due to mitral stenosis, primary failure of the right ventricle with tricuspid regurgitation, restrictive cardiomyopathy or constrictive pericarditis.

An important characteristic of cardiac cirrhosis is the absence of the intrahepatic obstruction of the portal vein resulting in the absence of hepatic portal hypertension.

Transient elastography is a non-invasive test to quantify liver stiffness, which is increased in patients with acute as well as chronic HF. In some studies, stiffness values were correlated with the level of N-terminal pro-brain natriuretic peptide (NT-proBNP). The elimination of congestion leads to the reduction, but not the normalization of the stiffness. Impairment of hepatic function may have far-reaching consequences, including a negative effect on myocardial function, but these relationships have not been extensively explored. The liver plays a key role in proproteosynthetic and metabolic functions and in the elimination of circulating endotoxins. An impaired microcirculation causes a decrease in endotoxin clearance and an increase in the secretion of proinflammatory cytokines. Immune activation negatively affects nutrition and the metabolism of iron and participates in cardiac cachexia and anaemia.

Clinical presentation

We distinguished two phenotypes of manifestations of hepatic lesions. The congestive (venostasis) phenotype dominates in most patients and is caused by an acute worsening of HF. Perfusion disorder is associated with the ischaemic phenotype. Isolated ischaemic impairment is rare. Ischaemic lesions of the liver, sometimes inappropriately called ischaemic hepatitis, develop due to rapid and significant decrease in the perfusion of the liver resulting from a prolonged hypotension. Hypoxemia can also contribute to ischaemic lesions. The mixed forms of liver impairment are the most common in acute decompensated HF.

Congestive (venostasis) liver dysfunction is clinically manifested by pain in the right hypochondrium and epigastrum and heaviness after eating. Gastrointestinal signs may be significant and are caused by splanchnic congestion and increased intra-abdominal pressure. Significant gastrointestinal symptomatology is typical, especially in adolescents and young adults. According to one analysis, abdominal pain was the only symptom in 23% of the cases in adolescents with the first manifestation of HF.
echogenicity may increase with advanced
25% of patients with right HF, especially splenomegaly.
During physical examinations. Ascites is present approximately in
in our case report.
Acalculous cholecystitis (14), which was the case in one patient
thickening of the gallbladder and the intestinal walls due to
splanchnic congestion.

Pain in the right hypochondrium with gallbladder wall thick-
ening and hyperbilirubinemia is sometimes misinterpreted as
acalculous cholecystitis (14), which was the case in one patient
in our case report.

The direction of blood flow in the hepatic veins is forward
only during diastole of the chamber, while the flow during systole,
with concomitant tricuspid regurgitation, is usually reversed. Un-
der normal conditions, the flow in the portal vein is continuous or
a slightly waving hepatopetal flow, which changes to a pulsatile
pattern, sometimes with a visible hepatofugal phase during systole
in advanced HF and congestion (Fig. 2) (15).

Chronic hepatic congestion changes the physical quality of
the liver. In patients with chronic HF, liver stiffness is related to
venous pressure and fibrosis. Some studies suggested that mea-
surement using acoustic elastography could be an indicator of
treatment’s success in HF (16). Liver stiffness may predict the
outcome in patients after left ventricular assist device (LVAD)
implantation (17).

In laboratory tests, a congestive hepatic lesion is manifested by
hyperbilirubinemia with a predominant increase of conjugated
bilirubin (direct bilirubin) and slightly elevated alkaline phospha-
tase and GGT levels. The concentration of transaminases (AST,
ALT) is usually normal or only slightly increased. The proteo-
synthetic liver function is normal or slightly worsened, as reflected
by an increased prothrombin time (PT), which does not respond
to the administration of vitamin K. Hypoalbuminaemia is usu-
ally present in advanced HF in patients with cardiac cachexia or
other disorders, such as enteropathy associated with the loss of
protein (18–20).

Ischaemic damage, also called hypoxic hepatopathy, shock liver
or ischaemic hepatitis, is a disorder that occurs as the result of a
significant decrease in liver perfusion and leads to centrilobular
hepatocyte necrosis. Hypoperfusion itself is usually not sufficient
to produce centrilobular necrosis. In many patients, hypoxemia
caused by pulmonary comorbidities can be identified as an additive
cause. The ischaemic lesion is manifested by the sudden increase
(often more than 100 times) in serum transaminases, along with
an increase in lactate dehydrogenase (LDH), PT and bilirubin,
but jaundice develops only rarely. If the treatment is successful,
laboratory values quickly return to the normal level. Ischaemic
aetiology is the cause of liver failure in approximately 5% of in-
patients admitted to departments specializing in acute liver failure
and liver transplant and is associated with hospital mortality rates
higher than 50%. The strongest predictor of mortality is the car-
diac index (CI) and its changes during treatment. At the time of
admission, the average CI has been reported to be 1.6 l/min/m² in
patients, who died and 2.1 l/min/m² in patients, who survived (21).

Congestion and hypoperfusion, two basic mechanisms leading
to liver damage, are often combined. Van Dreusena et al (22)
documented the link between a hepatic dysfunction and the hae-
modynamic profile in patients with HF. Increased central venous
pressure (CVP) was associated with an increase in all indicators of
liver dysfunction, especially direct bilirubin and GGT. Increases
in AST, ALT and total bilirubin levels were related to a low CI.

Table 1 provides a review of the typical laboratory changes in
border phenotypes of liver dysfunction in HF.

Renal hypoperfusion, congestion and increased abdominal
pressure are also major determinants of renal function impairment
in decompensated HF. Several research groups have pointed out
that the dominant problem is an increased renal venous pressure
rather than low cardiac output as was previously proposed (23, 24).

Prognostic and therapeutic implications of liver disorder in HF

The recognition and understanding of liver lesions in HF is
essential for the treatment and prognosis.

---

| Parameter | Congestion (Increased CVP) | Hypoperfusion (Low Cardiac Output) |
|-----------|-----------------------------|-----------------------------------|
| AST       | ↑↑                          | ↑↑↑                               |
| ALT       | ↑↑                          | ↑↑                                |
| TB        | ↑                           | ↑↑↑                               |
| DB        | ↑↑↑                         | ↑                                  |
| GGT       | ↑↑↑                         | 0↑                                 |
| ALP       | ↑↑↑                         | 0↑                                 |
| LDH       | ↑                           | ↑                                  |

ALP – alkaline phosphatase, ALT – alanine aminotransferase, AST – aspartate aminotransferase, CVP – central venous pressure, DB – direct bilirubin, GGT – gamma-glutamyltransferase, LDH – lactate dehydrogenase, TB – total bilirubin
Increased total bilirubin and decreased albumin in patients without a history of primary liver disease, who were admitted to the hospital for acute HF, were associated with a higher risk of rehospitalization and death in the following months (2, 4). Hypoalbuminemia appears to be a significant indicator of poor short-term prognosis in functional New York Heart Association (NYHA) class III / IV patients and patients with HF undergoing surgery (25).

In the study that analysed 330 patients with HF, Poelzl et al. (3) demonstrated the prognostic significance of GGT on other clinical and biological prognostic markers. The predictive value of increased GGT is higher in patients with milder (NYHA I/II) rather than severe (NYHA III / IV) symptoms.

Liver dysfunction is also an important prognostic factor after the implantation of an LVAD. Data analysis confirmed that liver dysfunction, quantified by the Model for End-Stage Liver Disease (MELD) score, was a simple and significant predictor of bleeding risk and death after LVAD implantation. The MELD score is calculated from serum creatinine, total bilirubin, sodium and international normalized ratio (INR) values. Patients with a MELD score $\geq 17$ had 2.5 times higher risk of death within 6 months after LVAD implantation (26, 27). Histological changes and the extent of fibrosis in liver samples obtained by trans-jugular biopsy could be the determining factors for risk assessment of LVAD implantation and the contraindications of this procedure (28).

The recognition of liver dysfunction also affects the patient management. The congestive phenotype should be treated with diuretics or elimination therapy. Hepatic and splanchnic congestion indicates a right ventricle failure, and treatment should focus on the volume and pressure unloading of the right ventricle. However, if the ischaemic/hypoxic phenotype is dominant, it is appropriate to initiate or intensify the therapy aimed to increase the perfusion and oxygenation.

In patients with HF and impaired hepatic function, drug hepatotoxicity and the role of the liver in the drug effects and degradation should be considered. Liver dysfunction may reduce the effect of medications, such as prodrugs (e.g., clopidogrel). However, drugs degraded and excreted by the hepatic route can accumulate. Cardiovascular pharmacotherapy, amiodarone, statins, certain ACE inhibitors, diltiazem and verapamil have a higher risk of accumulation and increased toxicity. Special attention should be given to anticoagulant therapy with vitamin K antagonists, which have a high risk of accumulation.

**Iulustrative cases reports**

**Congestive HF with systemic congestion imitating acute cholecystitis**

A 59-year-old patient with a history of ST elevation myocardial infarction 7 years previously, arterial hypertension and bronchial asthma was presented to the emergency department due to a severe pain in the right hypochondrium and nausea. He did not have a chest pain. Recently, he had experienced an increased fatigue, shortness of breath during physical activity and swelling in the ankles in the evening. The patient was obese.

A physical examination revealed an irregular heart beat with two heart sounds, a faint systolic murmur at the apex and breathing with wheezing during prolonged expiration. His blood pressure was 155/85 mmHg. ECG confirmed atrial fibrillation. His heart rate was 68/min, a QS configuration was present in V1–V3 leads, and the ST segment did not exhibit elevation or depression. A chest X-ray showed an increased transverse diameter of the heart, without other pathology. Laboratory tests detected a mild leucocytosis, increased direct bilirubin and GGT and slightly increased C-reactive protein, cardiospecific enzymes were normal. Ultrasonography of the gallbladder and liver showed an enlargement of the liver, gallbladder wall thickening, no gallstones and a small quantity of free fluid in the abdominal cavity located mainly peripherically (Fig. 3). Worsening dyspnoea was predicted to be associated with bronchial asthma and swelling in the ankles after the use of amiodipine for arterial hypertention. Surgeons suspected acalculous cholecystitis. Spasmolytic and antibiotic infusions did not improve the clinical status. A cholecystectomy was indicated. During the internal preoperative examination, the cardiologist reviewed the diagnosis and suspected a congestive HF with systemic congestion. The NT-proBNP level was significantly increased (3460 pg/ml).

Diuretic therapy and intensification of antihypertensive medication quickly led to the improvement of clinical status, including relief of pain in the right hypochondrium. Echocardiography showed a mildly dilated dysfunctional left ventricle with a reduced ejection fraction (36 %), moderate mitral regurgitation and a mildly dilated right ventricle with a moderate tricuspid regurgitation. The systolic pulmonary artery pressure was estimated to be 70 mmHg.

**Acute liver dysfunction as the dominant symptom of acute HF**

An 18-year-old healthy patient presented to a general practitioner complaining of low-grade fever, fatigue during ordinary physical activity, abdominal pain and subicterus. Laboratory tests detected significantly increased levels of ALT and AST (ALT 14.8 μmol/l, AST 15.4 μmol/l). The patient was admitted to the
infectious disease department with suspected infectious hepatitis. Serological tests did not confirm a viral aetiology of the liver impairment. Abdominal ultrasonography revealed hepatosplenomegaly and ascites. A chest X-ray did not show any pathological changes. The patient was transferred to the Department of Internal Medicine with a suspected autoimmune hepatitis and treated with the hepatoprotective drugs and glucocorticoids. Gradually decreasing diuresis was observed and pleural effusions and swelling developed. This condition was diagnosed as hepatorenal syndrome. The patient became short of breath at rest, and an orthopneic position was observed. After consultation with a cardiologist, a diagnosis of acute HF was established. Echocardiography showed a severe dysfunction of a mildly dilated left ventricle. Coronagraphy results were normal. Magnetic resonance imaging (MRI) confirmed a reduced ejection fraction of the left ventricle (17%) and intramyocardial “late enhancement”. In accordance with the MRI results, an endomyocardial biopsy revealed chronic myocarditis and myocardial fibrosis, and the viral genomes of the eight most common viruses were not found. Conservative treatment for HF and immunosuppression therapy was initiated, and the patient was stabilized over the next year. After this period, HF resistant to treatment developed, and the patient underwent a heart transplant.

References

1. Jolliffe N. Liver Function in Congestive Heart Failure. J Clin Invest 1930; 8: 419–433.
2. Ambrosy AP, Vaduganathan M, Huffman MD et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J of heart failure 2012; 14 (3): 302–311.
3. Poelzl G, Ess M, Mussner-Seeker C et al. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest 2012; 42 (2): 153–163.
4. Nikolau M, Parissis J, Yilmaz MB et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013; 34 (10): 742–749.
5. Allen LA, Felker GM, Pocock S et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Failure 2009; 11 (2): 170–177.
6. Dooley JS LA, Burroughs A, Heatcote EJ, Sherlock’s Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011.
7. Rappaport AM. Hepatic blood flow: morphologic aspects and physiologic regulation. Intern Rev Physiol 1980; 21: 1–63.
8. Verbrugge FH, Dupont M, Steels P et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Amer Coll Cardiol 2013; 62 (6): 485–495.
9. Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Brit Heart J 1951; 13 (3): 273–293.
10. Hopper I, Kemp W, Porapakkham P et al. Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography. Eur J Heart Failure 2012; 14 (6): 621–627.
11. Alegre F, Herrero JL, Inarraiaegui M et al. Increased liver stiffness values in patients with heart failure. Acta gastro-entrol Belg 2013; 76 (2): 246–250.
12. Valentova M, von Haschling S, Doehner W et al. Liver dysfunction and its nutritional implications in heart failure. Nutrition 2013; 29 (2): 370–378.
13. Hollander SA, Addonizio LJ, Chin C et al. Abdominal complaints as a common first presentation of heart failure in adolescents with dilated cardiomyopathy. Amer J Emerg Med 2013; 31 (4): 684–686.
14. Huffman JL, Schenker S. Acute acaulcus cholecystitis: a review. Clinical gastroenterology and hepatology: the official clinical practice. J Amer Gastroenterol Ass 2010; 8 (1): 15–22.
15. Goncalvesova E, Lesny P, Luknar M et al. Changes of portal flow in heart failure patients with liver congestion. Bratisl Lek Listy 2010; 111 (12): 635–639.
16. Yoshitani T, Asakawa N, Sakakibara M et al. Value of Virtual Touch Quantification Elasticography for Assessing Liver Congestion in Patients With Heart Failure. Circulation 2016; 80 (5): 1187–1195.
17. Putthoff A, Schettler A, Attia D et al. Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study. J Heart Lung Transplantation 2015; 34 (12): 1586–1594.
18. Auer J. What does the liver tell us about the failing heart? Eur Heart J 2013; 34 (10): 711–714.
19. Cogger VC, Fraser R, Le Couteur DG. Liver dysfunction and heart failure. Ameri J Cardiol 2003; 91 (11): 1399.
20. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Intern J Angiol 2011; 20 (3): 135–142.
21. Saner FH, Heuer M, Meyer M et al. When the heart kills the liver: acute liver failure in congestive heart failure. Eur J Med Res 2009; 14: 541–546.
22. Van Deursen VM, Damman K, Hillege HL et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Cardiac Failure 2010; 16 (1): 84–90.
23. Nguyen VQ, Gadiraju TV, Patel H et al. Intra-abdominal Hypertension: An Important Consideration for Diuretic Resistance in Acute Decompensated Heart Failure. Clin Cardiol 2016; 39 (1): 37–40.
24. Demesova E, Goncalvesova E, Slezk P et al. Functional and circulatory renal changes in advanced heart failure. Bratisl Lek Listy 2015; 116 (2): 83–87.
25. Samsky MD, Patel CB, DeWald TA et al. Cardiohepatic Interactions in Heart Failure an Overview and Clinical Implications. J Amer Coll Cardiol 2013; 61 (24): 2397–2405.
26. Matthews JC, Pagani FD, Haft JW et al. Model for End-Stage Liver Disease Score Predicts Left Ventricular Assist Device Operative Transfusion Requirements, Morbidity, and Mortality. Circulation 2010; 121 (2): 214–220.
27. Yang JA, Kato TS, Shulman BP et al. Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. J Heart Lung Transplantation 2012; 31 (6): 601–610.
28. Sundaram V, Fang JC. Gastrointestinal and Liver Issues in Heart Failure. Circulation 2016; 133 (17): 1696–1703.

Received October 6, 2017. Accepted November 9, 2017.